Compare Johnson & Johnson with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROCE of 432,803.06%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.26 times
3
Poor long term growth as Operating profit has grown by an annual rate 0.96% of over the last 5 years
4
Flat results in Jun 25
5
With ROCE of 23.24%, it has a very attractive valuation with a 5.05 Enterprise value to Capital Employed
6
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
USD 704,584 Million (Large Cap)
31.00
NA
1.92%
0.34
27.89%
8.64
Revenue and Profits:
Net Sales:
24,068 Million
(Quarterly Results - Mar 2026)
Net Profit:
5,235 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.34%
0%
3.34%
6 Months
19.49%
0%
19.49%
1 Year
46.84%
0%
46.84%
2 Years
53.17%
0%
53.17%
3 Years
38.99%
0%
38.99%
4 Years
25.32%
0%
25.32%
5 Years
37.45%
0%
37.45%
Johnson & Johnson for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.67%
EBIT Growth (5y)
4.60%
EBIT to Interest (avg)
24.32
Debt to EBITDA (avg)
0.26
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.78
Tax Ratio
17.14%
Dividend Payout Ratio
46.59%
Pledged Shares
0
Institutional Holding
74.67%
ROCE (avg)
432,803.06%
ROE (avg)
387,416.25%
Valuation key factors
Factor
Value
P/E Ratio
31
Industry P/E
Price to Book Value
8.64
EV to EBIT
28.58
EV to EBITDA
22.11
EV to Capital Employed
6.70
EV to Sales
7.78
PEG Ratio
2.21
Dividend Yield
1.92%
ROCE (Latest)
23.43%
ROE (Latest)
27.89%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 301 Schemes (26.15%)
Foreign Institutions
Held by 764 Foreign Institutions (16.86%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
24,068.00
24,562.00
-2.01%
Operating Profit (PBDIT) excl Other Income
8,579.00
7,390.00
16.09%
Interest
418.00
490.00
-14.69%
Exceptional Items
-771.00
-1,032.60
25.33%
Consolidate Net Profit
5,235.00
5,116.00
2.33%
Operating Profit Margin (Excl OI)
273.20%
219.00%
5.42%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -2.01% vs 2.38% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 2.33% vs -0.70% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
94,178.00
88,819.00
6.03%
Operating Profit (PBDIT) excl Other Income
33,627.00
28,162.00
19.41%
Interest
1,490.00
1,150.00
29.57%
Exceptional Items
5,424.00
-6,241.80
186.90%
Consolidate Net Profit
26,804.00
14,066.00
90.56%
Operating Profit Margin (Excl OI)
277.40%
234.40%
4.30%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 6.03% vs 4.31% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 90.56% vs 5.55% in Dec 2024
About Johnson & Johnson 
Johnson & Johnson
Pharmaceuticals & Biotechnology
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Company Coordinates 
Company Details
1 Johnson And Johnson Plz , NEW BRUNSWICK NJ : 08933-0001
Registrar Details






